Skip to content
Ashvattha Therapeutics
Ashvattha Therapeutics
  • Home
  • About Us
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • D6-B483
    • OP-801
    • D-4517.2
    • OP-101
  • News
  • Careers
  • Contact
Ashvattha Therapeutics
  • Home
  • About Us
    • Senior Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • D6-B483
    • OP-801
    • D-4517.2
    • OP-101
  • News
  • Careers
  • Contact

Month: September 2021

Ashvattha Therapeutics Announces Two Oral Presentations at the World Molecular Imaging Congress 2021

September 29, 2021 by ashvatthaadmin

Ashvattha will present two oral presentations at the virtual World Molecular Imaging Congress (WMIC), on October 5-8, 2021.

Categories Press Release

Ashvattha Therapeutics Announces Participation at Upcoming Investor Conferences

September 9, 2021 by ashvatthaadmin

Ashvattha Chairman, CEO and President Jeffrey Cleland, Ph.D., will be presenting at various virtual and in-person investor conferences in September and October.

Categories Press Release

Recent Posts

  • Ashvattha Therapeutics Announces Preclinical Data at the 2022 Alzheimer’s Association International Conference (AAIC) Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET
  • Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes
  • Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 Alzheimer’s Association International Conference (AAIC)
  • Ashvattha Therapeutics Announces Presentation of Preclinical Data at the 2022 Neurofibromatosis (NF) Conference Demonstrating the Potential of Hydroxyl Dendrimer Therapeutics to Reduce Toxicity in Targeted Treatment of Plexiform Neurofibroma
  • Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based Therapeutics at the 2022 Neurofibromatosis (NF) Conference

Recent Comments

    Archives

    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • September 2021
    • June 2021
    • May 2021
    • April 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020

    Categories

    • In the News
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Howdy, this is Creativo

    We just added a brand new Off Canvas Sidebar. You can change the content you see here by going to Appearance -> Widgets -> Off Canvas Sidebar.

    Of course you can also change the design of this sidebar by going to Appearance -> Theme Options -> Off Canvas Sidebar.

    Change everything from: background color, font color, font size, sidebar headings and more.

    © Copyright 2022 Ashvattha Therapeutics.
    • Privacy Policy
    © 2022 Ashvattha Therapeutics • Built with GeneratePress